

SAFETY DATA SHEET

ScreenTape 2

SECTION 1: Identification of the substance/mixture and of the company/undertaking

This product is considered an article. This Safety Data Sheet is written based on the encapsulated substance or mixture in this article.

1.1 Product identifier

Product name : ScreenTape 2
Part no. : 5067-5365, 5067-5576, 5067-5579, 5067-5588, 5067-5592, 5067-5634

1.2 Relevant identified uses of the substance or mixture and uses advised against

Identified uses : For research use only.
 7 ScreenTape / Box
 5067-5365 Genomic DNA ScreenTape
 5067-5576 RNA ScreenTape
 5067-5579 High Sensitivity RNA ScreenTape
 5067-5588 D5000 ScreenTape
 5067-5592 High Sensitivity D5000 ScreenTape
 5067-5634 High Sensitivity Genomic DNA ScreenTape

Uses advised against : Not for use in diagnostic procedures (RUO).

1.3 Details of the supplier of the safety data sheet

Agilent Technologies Deutschland GmbH
 Hewlett-Packard-Str. 8
 76337 Waldbronn
 Germany
 0800 603 1000

e-mail address of person responsible for this SDS : pdl-msds_author@agilent.com

1.4 Emergency telephone number

Emergency telephone number (with hours of operation) : CHEMTREC®: +353 1 901 4670

SECTION 2: Hazards identification

This article, when used under reasonable conditions and in accordance with the directions for use, should not present a health hazard. The substance or mixture is encapsulated in the article. Only if released due to use or processing of the article in a manner not in accordance with the product's directions for use it may present potential health and safety hazards.

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

H319	SERIOUS EYE DAMAGE/EYE IRRITATION	Category 2
H317	SKIN SENSITISATION	Category 1

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

Ingredients of unknown toxicity : Percentage of the mixture consisting of ingredient(s) of unknown acute dermal toxicity: 1 - 10%
 Percentage of the mixture consisting of ingredient(s) of unknown acute inhalation toxicity: 1 - 10%
 Percentage of the mixture consisting of ingredient(s) of unknown acute oral toxicity: 1 - 10%

Ingredients of unknown ecotoxicity : Contains 3% of components with unknown hazards to the aquatic environment

See Section 16 for the full text of the H statements declared above.

SECTION 2: Hazards identification

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H317 - May cause an allergic skin reaction.
H319 - Causes serious eye irritation.

Precautionary statements

Prevention : P280 - Wear protective gloves. Wear eye or face protection.
P261 - Avoid breathing dust.

Response : P302 + P352 - IF ON SKIN: Wash with plenty of water.
P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention.
P362 + P364 - Take off contaminated clothing and wash it before reuse.

Storage : Not applicable.

Disposal : P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.

Hazardous ingredients : 2-methylisothiazol-3(2H)-one

Supplemental label elements : Not applicable.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles : Not applicable.

Special packaging requirements

Tactile warning of danger : Not applicable.

2.3 Other hazards

Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII : This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

Other hazards which do not result in classification : None known.

SECTION 3: Composition/information on ingredients

This article, when used under reasonable conditions and in accordance with the directions for use, should not present a health hazard. The substance or mixture is encapsulated in the article. Only if released due to use or processing of the article in a manner not in accordance with the product's directions for use it may present potential health and safety hazards.

3.2 Mixtures : Mixture

ScreenTape 2

SECTION 3: Composition/information on ingredients

Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Type
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	EC: 230-237-7 CAS: 6976-37-0	<3	Eye Dam. 1, H318	-	[1]
2-methylisothiazol-3(2H)-one	EC: 220-239-6 CAS: 2682-20-4 Index: 613-326-00-9	<0.01	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071 See Section 16 for the full text of the H statements declared above.	ATE [Oral] = 285.5 mg/kg ATE [Dermal] = 242 mg/kg ATE [Inhalation (dusts and mists)] = 0.11 mg/l Skin Sens. 1, H317: C ≥ 0.0015% M [Acute] = 10 M [Chronic] = 1	[1]

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Type

[1] Substance classified with a health or environmental hazard

Occupational exposure limits, if available, are listed in Section 8.

SECTION 4: First aid measures

4.1 Description of first aid measures

- Eye contact** : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.
- Inhalation** : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Skin contact** : Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.
- Ingestion** : Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.
- Protection of first-aiders** : No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

ScreenTape 2

SECTION 4: First aid measures

4.2 Most important symptoms and effects, both acute and delayed

Over-exposure signs/symptoms

- Eye contact** : Adverse symptoms may include the following:
 pain or irritation
 watering
 redness
- Inhalation** : No specific data.
- Skin contact** : Adverse symptoms may include the following:
 irritation
 redness
- Ingestion** : No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

- Notes to physician** : In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours.
- Specific treatments** : No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media** : Use an extinguishing agent suitable for the surrounding fire.
- Unsuitable extinguishing media** : None known.

5.2 Special hazards arising from the substance or mixture

- Hazards from the substance or mixture** : No specific fire or explosion hazard.
- Hazardous combustion products** : Decomposition products may include the following materials:
 carbon dioxide
 carbon monoxide
 nitrogen oxides

5.3 Advice for firefighters

- Special precautions for fire-fighters** : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
- Special protective equipment for fire-fighters** : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- For non-emergency personnel** : No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
- For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

ScreenTape 2

SECTION 6: Accidental release measures

6.2 Environmental precautions : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Move containers from spill area. Avoid dust generation. Using a vacuum with HEPA filter will reduce dust dispersal. Place spilled material in a designated, labeled waste container. Dispose of via a licensed waste disposal contractor.

6.4 Reference to other sections : See Section 1 for emergency contact information.
See Section 8 for information on appropriate personal protective equipment.
See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Protective measures : Put on appropriate personal protective equipment (see Section 8). Do not get in eyes or on skin or clothing. Avoid contact with eyes, skin and clothing. Do not ingest. Empty containers retain product residue and can be hazardous. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Do not reuse container. Persons with a history of skin sensitization problems should not be employed in any process in which this product is used.

Advice on general occupational hygiene : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Storage : Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations : Industrial applications, Professional applications.

Industrial sector specific solutions : Not available.

SECTION 8: Exposure controls/personal protection

Since the hazardous ingredient in this article is encapsulated, the risk of exposure by inhalation, ingestion, skin contact and eyes contact is minimum.

8.1 Control parameters

Occupational exposure limits

No exposure limit value known.

Biological exposure indices

No exposure indices known.

SECTION 8: Exposure controls/personal protection

Recommended monitoring procedures : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

DNELs/DMELs

Product/ingredient name	Result	
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	DNEL - Workers - Long term - Dermal	14 mg/kg bw/day
	DNEL - Workers - Long term - Inhalation	24.68 mg/m ³
2-methylisothiazol-3(2H)-one	DNEL - General population - Long term - Inhalation	0.021 mg/m ³
	DNEL - Workers - Long term - Inhalation	0.021 mg/m ³
	DNEL - General population - Long term - Oral	0.027 mg/kg bw/day
	DNEL - General population - Short term - Inhalation	0.043 mg/m ³
	DNEL - Workers - Short term - Inhalation	0.043 mg/m ³
	DNEL - General population - Short term - Oral	0.053 mg/kg bw/day

PNECs

Not available.

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.

ScreenTape 2

SECTION 8: Exposure controls/personal protection

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance

- Physical state** : Solid.
- Colour** : Not available.
- Odour** : Not available.
- Odour threshold** : Not available.
- Melting point/freezing point** : Not available.
- Boiling point or initial boiling point and boiling range** : Not available.
- Flammability** : Not available.
- Lower and upper explosion limit/flammability limit** : Not applicable.
- Flash point** : Not applicable.
- Auto-ignition temperature** : Not applicable.
- Decomposition temperature** : Not available.
- pH** : 8
- Viscosity** : Dynamic (room temperature): Not available.
Kinematic (room temperature): Not available.
Kinematic (40°C): Not available.

Solubility	Media	Result
	water	Soluble

- Partition coefficient: n-octanol/water** : Not applicable.
- Vapour pressure** : Not available.
- Relative density** : Not available.
- Relative vapour density** : Not applicable.

Particle characteristics

- Median particle size** : Not available.

9.2 Other information

9.2.1 Information with regard to physical hazard classes

- Explosive properties** : Not available.
- Oxidising properties** : Not available.

9.2.2 Other safety characteristics

- Evaporation rate** : Not available.
- Physical/chemical properties comments** : Not available.

ScreenTape 2

SECTION 10: Stability and reactivity

- 10.1 Reactivity** : No specific test data related to reactivity available for this product or its ingredients.
- 10.2 Chemical stability** : The product is stable.
- 10.3 Possibility of hazardous reactions** : Under normal conditions of storage and use, hazardous reactions will not occur.
- 10.4 Conditions to avoid** : No specific data.
- 10.5 Incompatible materials** : May react or be incompatible with oxidising materials.
- 10.6 Hazardous decomposition products** : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Product/ingredient name	Result
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	Rat - Female - Oral - LD50 >2000 mg/kg
2-methylisothiazol-3(2H)-one	Rat - Male, Female - Oral - LD50 285.5 mg/kg
	Rat - Male, Female - Dermal - LD50 242 mg/kg
	Rat - Male, Female - Inhalation - LC50 Dusts and mists 0.11 mg/l [4 hours]

Conclusion/Summary [Product] : Not available.

Acute toxicity estimates

Product/ingredient name	Oral (mg/kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
2-methylisothiazol-3(2H)-one	285.5	242	N/A	N/A	0.11

Skin corrosion/irritation

Conclusion/Summary [Product] : Not available.

Serious eye damage/eye irritation

Conclusion/Summary [Product] : Not available.

Respiratory corrosion/irritation

Conclusion/Summary [Product] : Not available.

Respiratory or skin sensitization

Skin

Conclusion/Summary [Product] : Not available.

Respiratory

ScreenTape 2

SECTION 11: Toxicological information

Conclusion/Summary [Product] : Not available.

Germ cell mutagenicity

Conclusion/Summary [Product] : Not available.

Carcinogenicity

Conclusion/Summary [Product] : Not available.

Reproductive toxicity

Conclusion/Summary [Product] : Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on likely routes of exposure : Routes of entry anticipated: Oral, Dermal, Inhalation, Eyes.

Potential acute health effects

Eye contact : Causes serious eye irritation.
Inhalation : No known significant effects or critical hazards.
Skin contact : May cause an allergic skin reaction.
Ingestion : No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact : Adverse symptoms may include the following:
 pain or irritation
 watering
 redness
Inhalation : No specific data.
Skin contact : Adverse symptoms may include the following:
 irritation
 redness
Ingestion : No specific data.

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Short term exposure

Potential immediate effects : Not available.
Potential delayed effects : Not available.

Long term exposure

Potential immediate effects : Not available.
Potential delayed effects : Not available.

Potential chronic health effects

ScreenTape 2

SECTION 11: Toxicological information

- Conclusion/Summary [Product]** : Not available.
- General** : Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
- Carcinogenicity** : No known significant effects or critical hazards.
- Mutagenicity** : No known significant effects or critical hazards.
- Reproductive toxicity** : No known significant effects or critical hazards.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

- Conclusion/Summary [Product]** : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	Acute - LC50 - Fresh water	>100 mg/l [96 hours]
	Acute - NOEC - Fresh water	≥100 mg/l [96 hours]
	Acute - EC50 - Fresh water	>100 mg/l [48 hours]
	Acute - NOEC - Fresh water	≥100 mg/l [48 hours]
	Acute - EC50 - Fresh water	>100 mg/l [72 hours]
2-methylisothiazol-3(2H)-one	Acute - NOEC - Fresh water	100 mg/l [72 hours]
	Acute - EC50 - Fresh water	0.18 ppm [48 hours]
	Acute - LC50 - Fresh water	0.07 ppm [96 hours]
	Chronic - NOEC - Fresh water	4.93 mg/l [98 days]
	Chronic - NOEC - Fresh water	0.044 mg/l [21 days]

- Conclusion/Summary [Product]** : Not available.

12.2 Persistence and degradability

Product/ingredient name	Result		
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	Aerobic - 33 mg/l	11.89% [28 days] - Not readily	Aerobic - 33 mg/l
2-methylisothiazol-3(2H)-one	-	0% [28 days] - Not readily	-

- Conclusion/Summary [Product]** : Not available.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	-	-	Not readily
2-methylisothiazol-3(2H)-one	-	-	Not readily

12.3 Bioaccumulative potential

Product/ingredient name	LogP _{ow}	BCF	Potential
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	-2.26	-	Low
2-methylisothiazol-3(2H)-one	0.119	-	Low

12.4 Mobility in soil

Soil/water partition coefficient

ScreenTape 2

SECTION 12: Ecological information

Product/ingredient name	logKoc	Koc
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	1.3	21.7161
2-methylisothiazol-3(2H)-one	1.7	54.9187

Results of PMT and vPvM assessment

Product/ingredient name	PMT	P	M	T	vPvM	vP	vM
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	No	N/A	Yes	No	N/A	N/A	Yes
2-methylisothiazol-3(2H)-one	No	N/A	Yes	No	N/A	N/A	Yes

Mobility : Not available.**Conclusion/Summary** : The product does not meet the criteria to be considered as a PMT or vPvM.**12.5 Results of PBT and vPvB assessment****Regulation (EC) No. 1907/2006 [REACH]**

Product/ingredient name	PBT	P	B	T	vPvB	vP	vB
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	No	N/A	N/A	No	N/A	N/A	N/A
2-methylisothiazol-3(2H)-one	No	N/A	N/A	No	N/A	N/A	N/A

Regulation (EC) No. 1272/2008 [CLP]

Product/ingredient name	PBT	P	B	T	vPvB	vP	vB
2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol	No	N/A	N/A	No	N/A	N/A	N/A
2-methylisothiazol-3(2H)-one	No	N/A	N/A	No	N/A	N/A	N/A

Conclusion/Summary : The product does not meet the criteria to be considered as a PBT or vPvB.**Regulation (EC) No. 1272/2008 [CLP]****12.6 Endocrine disrupting properties****Conclusion/Summary [Product]** : The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.**12.7 Other adverse effects**

No known significant effects or critical hazards.

SECTION 13: Disposal considerations**13.1 Waste treatment methods****Product****Methods of disposal** : Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. The generation of waste should be avoided or minimised wherever possible. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.**Hazardous waste** : The classification of the product may meet the criteria for a hazardous waste.**Packaging****Methods of disposal** : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.

ScreenTape 2

SECTION 13: Disposal considerations

Special precautions : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

This Safety Data Sheet is written based on the encapsulated substance or mixture in this article. Since the hazardous ingredient is encapsulated, the risk of exposure by inhalation, ingestion, skin contact and eyes contact is minimum.

	ADR/RID	IMDG	IATA
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-
14.3 Transport hazard class(es)	-	-	-
14.4 Packing group	-	-	-
14.5 Environmental hazards	No.	No.	No.

Additional information

14.6 Special precautions for user : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Transport in bulk according to IMO instruments : Not available.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

None of the components are listed / The components are not impacted by a restriction

Labelling : Not applicable.

Other EU regulations

Ozone depleting substances (EU 2024/590)

Not listed.

Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

Persistent Organic Pollutants

ScreenTape 2

SECTION 15: Regulatory information

Not listed.

Seveso Directive

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

Inventory list

Australia	: All components are listed or exempted.
Canada	: All components are listed or exempted.
China	: All components are listed or exempted.
Eurasian Economic Union	: Russian Federation inventory : Not determined.
Japan	: Japan inventory (CSCL) : All components are listed or exempted. Japan inventory (ISHL) : All components are listed or exempted.
New Zealand	: All components are listed or exempted.
Philippines	: Not determined.
Republic of Korea	: All components are listed or exempted.
Taiwan	: All components are listed or exempted.
Thailand	: Not determined.
Turkey	: All components are listed or exempted.
United States	: All components are active or exempted.
Viet Nam	: Not determined.

15.2 Chemical safety assessment : This product contains substances for which Chemical Safety Assessments might still be required.

SECTION 16: Other information

🔍 Indicates information that has changed from previously issued version.

Abbreviations and acronyms	: ADN = European Provisions concerning the International Carriage of Dangerous Goods by Inland Waterway ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road ATE = Acute Toxicity Estimate B = Bioaccumulative BCF = Bioconcentration Factor CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement IATA = International Air Transport Association IMDG = International Maritime Dangerous Goods IMO = International Maritime Organization
-----------------------------------	---

ScreenTape 2

SECTION 16: Other information

M = Mobile
 N/A = Not available
 P = Persistent
 PBT = Persistent, Bioaccumulative and Toxic
 PMT = Persistent, Mobile and Toxic
 PNEC = Predicted No Effect Concentration
 RID = The Regulations concerning the International Carriage of Dangerous Goods by Rail
 RRN = REACH Registration Number
 SGG = Segregation Group
 T = Toxic
 vB = Very Bioaccumulative
 vM = Very Mobile
 vP = Very Persistent
 vPvB = Very Persistent and Very Bioaccumulative
 vPvM = Very Persistent and Very Mobile

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Eye Irrit. 2, H319 Skin Sens. 1, H317	Calculation method Calculation method

Full text of abbreviated H statements

H301 H311 H314 H317 H318 H319 H330 H400 H410 EUH071	Toxic if swallowed. Toxic in contact with skin. Causes severe skin burns and eye damage. May cause an allergic skin reaction. Causes serious eye damage. Causes serious eye irritation. Fatal if inhaled. Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects. Corrosive to the respiratory tract.
--	--

Full text of classifications [CLP/GHS]

Acute Tox. 2 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 Eye Dam. 1 Eye Irrit. 2 Skin Corr. 1B Skin Sens. 1 Skin Sens. 1A	ACUTE TOXICITY - Category 2 ACUTE TOXICITY - Category 3 SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 SKIN CORROSION/IRRITATION - Category 1B SKIN SENSITISATION - Category 1 SKIN SENSITISATION - Category 1A
--	---

Date of issue/ Date of revision : 26/07/2025

Date of previous issue : 30/09/2022

Version : 2

Notice to reader

Disclaimer: The information contained in this document is based on Agilent’s state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.